All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
#IACH2024
Bookmark this article
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 20, 2024
Zaineb Hasnaoui presents results from a retrospective analysis of patients with NDMM who underwent auto-HSCT.
The presentation characteristics and long-term outcomes were similar between patients aged ≤45 years and >45 years.
Follow our… pic.twitter.com/95RV7wBf9Z
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 20, 2024
Esther Ortega Vida, University Hospital of Jerez de la Frontera, shares findings from a real-world, single-center, retrospective study of the impact of novel therapies on survival in patients with MM.
Findings suggest that incorporating… pic.twitter.com/fSZpr7n4Ki
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 21, 2024
Zaineb Hasnaoui reports results from a retrospective analysis of the outcomes of patients with multiple myeloma and renal impairment who were treated with VTD triplet therapy and underwent auto-HSCT.
Survival outcomes in patients receiving… pic.twitter.com/avFcJTGZyz
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 21, 2024
Thierry Facon @univ_lille provides an update on treatment for elderly patients with NDMM.
They highlight results from IMROZ and BENEFIT trials, and discuss clinical considerations and potential future directions for the treatment of… pic.twitter.com/24i8LIl47T
Your opinion matters
3 votes - 34 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox